WASHINGTON — The Antiviral Drugs Advisory Committee of the Food and Drug Administration recommended the agency approve for preventative use Gilead’s AIDS treatment drug Truvada, according to MSNBC.
Testing has shown promise with high-risk patients in preventing HIV infection when taking the drug daily. Though concerns have been raised over the drug’s cost ($1,200 per month), the possibility for creating drug-resistant strains of the virus and side effects like nausea, HIV prevention specialists welcome the decision as part of a comprehensive toolkit to reducing new infections.
“Existing interventions have not reduced the number of new infections annually and new measures are needed,” Dr. John Mellors, chief of the infectious diseases division at the University of Pittsburgh, told MSNBC.
- Man charged in Md. trans murder sentenced to 30 years by Lou Chibbaro Jr. | posted on August 21, 2017
- Uganda activists hold secret Pride celebration by Helen Parshall | posted on August 21, 2017
- EXCLUSIVE: HRC, Chilean advocacy group to launch business index by Nicolás Levy | posted on August 22, 2017
- Recovering after Charlottesville by Richard J. Rosendall | posted on August 22, 2017
- ‘AHS: Cult’ trailer shows Trump’s win kicking off creepy clown cult by Mariah Cooper | posted on August 22, 2017